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We have recently designed a soluble synthetic peptide that functionally mimics the HIV-1
coreceptor CXCR4, which is a chemokine receptor that belongs to the family of seven-
transmembrane GPCRs.This CXCR4 mimetic peptide, termed CX4-M1, presents the three
extracellular loops (ECLs) of the receptor. In binding assays involving recombinant proteins,
as well as in cellular infection assays, CX4-M1 was found to selectively recognize gp120
from HIV-1 strains that use CXCR4 for cell entry (X4 tropic HIV-1). Furthermore, anti-HIV-
1 antibodies modulate this interaction in a molecular mechanism related to that of their
impact on the gp120–CXCR4 interaction.We could now show that the selectivity of CX4-M1
pertains not only to gp120 from X4 tropic HIV-1, but also to synthetic peptides presenting
the V3 loops of these gp120 proteins. The V3 loop is thought to be an essential part of the
coreceptor binding site of gp120 that contacts the second ECL of the coreceptor. We were
able to experimentally confirm this notion in binding assays using substitution analogs of
CX4-M1 and theV3 loop peptides, respectively, as well as in cellular infection assays.These
results indicate that interactions of the HIV-1 Env with coreceptors can be mimicked by
synthetic peptides, which may be useful to explore these interactions at the molecular
level in more detail.
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INTRODUCTION
Essentially all biological processes are initiated by specific inter-
actions between proteins and their ligands. The design and gen-
eration of molecules capable of mimicking the binding and/or
functional sites of proteins, represents a strategy for the explo-
ration and modulation of protein function through controlled
interference with the underlying binding events. In addition to
their basic significance, such protein mimetics are also useful tools
for a range of biomedical applications, in particular the inhibition
of protein–protein interactions.
In general, synthetic peptides can be considered adequate tools
for the mimicry of specific protein sites, since they can be generated
as exact copies of protein fragments, as well as in diverse chemical
modifications, which includes the incorporation of a large range
of non-proteinogenic amino acids, as well as the modification of
the peptide backbone (1). Apart from extending the chemical and
structural diversity presented by peptides, such modifications also
increase the proteolytic stability of the molecules, enhancing their
potential as drug candidates.
Entry of the human immunodeficiency virus (HIV-1), the
causative agent of the acquired immunodeficiency syndrome
(AIDS), into its host cell, as well as its replication, is mediated
by a range of specific interactions between viral and host cell pro-
teins (2–4). Peptides mimicking the binding sites of the involved
proteins are not only valuable tools to explore the respective inter-
actions at the molecular level, but also candidates for therapeutic
intervention through specific inhibition of these interactions (5).
HIV-1 enters its host cell by using its envelope (Env), which is com-
posed of the two glycoproteins gp120 and gp41. Env is located on
the virus surface, where it forms trimeric spikes (6, 7). While gp120
is important for the attachment of the virus to the cellular recep-
tor CD4, as well as coreceptors CXCR4 and CCR5, respectively,
gp41 mediates fusion of the viral and cellular membranes. Con-
sequently, peptides presenting fragments of Env proteins that are
involved in virus-cell contact and fusion, are promising candidates
for the inhibition of HIV-1 cell entry (8). In fact, the first and so far
only HIV-1 fusion inhibitor approved for clinical use is a 36-mer
peptide derived from gp41 (9, 10). The coreceptor binding site of
Env is located in the bridging sheet and V3 loop of gp120 (11).
This binding site, however, is properly exposed, i.e., accessible for
the coreceptor, only upon prior contact of Env with CD4, which
induces a conformational re-arrangement of gp120 (6, 7, 12, 13).
According to their coreceptor usage (CXCR4 or CCR5), HIV-1
strains are classified as X4- and R5-tropic, respectively (14).
We have recently extended the scope of using scaffolded and
assembled peptides for the synthetic mimicry of large, discontin-
uous protein binding sites, to extracellular domains of transmem-
brane proteins, i.e., the HIV-1 coreceptor CXCR4. The functional-
ity of this CXCR4 mimetic peptide was demonstrated by its ability
to discriminate between gp120 from X4- and R5-tropic HIV-1
in binding assays involving recombinant proteins, as well as in
cellular infection assays (15).
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In this study, we aimed at exploring, using the gp120–CXCR4
interaction as a model, the scope and limitations of mimicking
protein–protein interactions not only through protein–peptide,
but also through peptide–peptide interactions, by means of mim-
icking the binding sites of both proteins through peptides. The
larger degree of flexibility of linear,unfolded peptides,as compared
to folded proteins, is generally thought to limit their potential for
high-affinity interactions, since the reduction of conformational
entropy is a major barrier that has to be overcome in protein bind-
ing (16). It has been shown, however, that intrinsically unfolded
peptides can adopt defined conformations once they are bound to
their target protein (17). Here, we asked the question if a protein–
protein interaction can be mimicked by peptides presenting the
binding sites of the proteins for each other. Specifically, we set out
to generate peptides that mimic the V3 loops of various HIV-1
strains, and to assay their ability to specifically bind to the CXCR4
mimetic peptide CX4-M1 (Figure 1).
MATERIALS AND METHODS
MATERIALS
Gp120IIIB was obtained from ImmunoDiagnostics, gp120MN,
gp120ADA, and gp120HxBc2 from Immune Technology, sCD4 from
Sino Biological, and mAb 447-52D from Polymun. MAb 3869 and
gp120BAL were obtained through the NIH AIDS Research and Ref-
erence Reagent Program. Fmoc-amino acids were obtained from
Iris Biotech.
PEPTIDE SYNTHESIS
Peptides (see Tables 3 and 5 for sequences) were synthesized
as C-terminal amides by Fmoc/t-Bu-based solid-phase synthe-
sis on 100 mg TentaGel S RAM resin (0.23 mmol/g) using an
automated multiple peptide synthesizer (SYRO from MultiSyn-
Tech). In a standard coupling cycle, five eq. of Fmoc-amino
acid/DIC/HOBt in DMF were coupled twice for 60 min, fol-
lowed by a capping step using a mixture of acetic anhy-
dride/pyridine/DMF (1:2:3; 30 min). The biotin moiety of CX4-
M1 and its variants was introduced by coupling three eq. of Fmoc-
Lys(biotin)/DIC/HOBt in DMF over night. The Fmoc group was
removed using 20% piperidine/DMF (20 min). The N-terminal
amino groups were acetylated (CX4-M1 and its variants), fluo-
resceinylated (all V3 loop peptides), and biotinylated (V3HxBc2
and V3BAL), respectively. Fluorescein was introduced by cou-
pling two eq. fluorescein-N -hydroxysuccinimide/5% DIPEA in
DMF in the dark overnight, and biotin by coupling three eq. of
biotin/DIC/HOBt overnight.
Peptides were cleaved from the resin using Reagent
K (TFA/water/phenol/thioanisole/1,2-ethanedithiol; 82.5:5:5:2.5),
precipitated in a cold 1:1 mixture of cyclohexane and tert-butyl
methyl ether, extracted with water, lyophilized twice, and purified
by preparative HPLC (conditions: column: Dr. Maisch Reprosil
100, 250 mm× 25 mm, flow rate: 9 mL/min, gradient: 30–60%
(CX4-M1 and variants) and 15–45% (V3 loop peptides) ace-
tonitrile in H2O (both containing 0.1% TFA) in 60 min and
UV detection at 216 and 280 nm). Peptides were cyclized by
air oxidation at 0.3 mg/mL in 50% acetonitrile in 0.1 M ammo-
nium acetate, pH 8, for 3 days. Absence of free SH groups was
confirmed by a negative Ellman’s test (18). Full length V3 loop
FIGURE 1 | Structure-based design of peptides presenting the V3 loop
of gp120 (A), and the three extracellular loops of CXCR4 (CX4-M1) (B).
Peptides were designed based on crystal structures of a gp120–CD4
complex (pdb: 2b4c) and CXCR4 (pdb: 3odu), respectively.
peptides were characterized by MALDI-TOF mass spectrometry
(MS) using MTP 384 massive target, Autoflex 1 (Bruker Dal-
tonics), and FlexAnalysis Software (Bruker Daltonics). CX4-M1
and its variants, as well as truncated V3 loop peptides were
characterized by analytical HPLC with online ESI-MS detec-
tion (LC-MS). Conditions: column: Phenomenex Kinetex 2.6µM
C18 100Å, 50 mm× 2.1 mm, flow rate: 0.4 mL/min, gradient: 5–
95% acetonitrile in H2O (both containing 0.1% TFA) in 15 min.
MS data of all peptides are listed in Tables 1 and 2. Stock
solutions of purified peptides were prepared at 1 mM in 50%
acetonitrile/H2O.
DIRECT ELISA
High binding microtiter plates (Immulon 2HB) were coated
overnight at 4°C with streptavidin (4µg/mL) in 0.1 M sodium
carbonate buffer pH 9.5. Unspecific binding was blocked with
1% BSA in 0.1 M phosphate buffer pH 7.2, 200µL/well for 1 h.
All following steps were performed using 0.1 M phosphate buffer
pH 7.2 containing 1% BSA (ELISA with V3 loop peptides) and
0.1% BSA (ELISA with gp120), respectively, as well as 0.01%
Tween 20. Plates were incubated with 100µL CX4-M1 variants
(0.5µM for binding to V3 loop peptides, 2.5µM for binding
to gp120), or biotin alone as a blank, for 2 h. Plates were then
incubated for 3 h with fluoresceinylated V3 loop peptides (250 or
100 nM), or gp120 (8.3 nM, either with or without 8.3 nM sCD4).
V3 loop peptides were detected using 100µL/well mouse anti-
fluorescein-HRP conjugate from antibodies online (3µg/mL) for
1 h. Gp120 was detected using a two antibody system. Sheep
anti-gp120 (D7324) from Aalto Bio Reagents (0.2µg/mL) was
added for 1 h, followed by a 1 h incubation with rabbit anti-sheep-
HRP conjugate from Dianova (3µg/mL), 100µL/well. Plates were
washed four times with 0.01% Tween 20 in 0.1 M phosphate
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Table 1 | MALDI-TOF mass spectrometry data of synthesized V3 loop
peptides.
Peptide Mcalc (g/mol) [M+H]+ [M+2H]2+
V3IIIB 4732.6 4733.5 2366.7
Fluo-V3HxBc2 4760.6 4762.3 2381.0
Bio-V3HxBc2 4628.5 4628.7 2315.2
V3MN 4724.4 4724.0 2362.0
Fluo-V3BAL 4503.1 4504.1 2252.5
Bio-V3BAL 4371.0 4371.8 2185.8
V3ADA 4537.1 4538.1 2269.4
V3HxBc2 R306A 4675.4 4676.1 2338.5
V3HxBc2 I307A 4718.4 4719.2 2360.0
V3HxBc2 R308A 4675.4 4676.3 2338.8
V3HxBc2 I309A 4718.4 4719.4 2360.5
V3HxBc2 Q310A 4703.4 4707.6 2352.9
V3HxBc2 R311A 4675.4 4676.0 2338.7
V3HxBc2 G312A 4774.5 4775.1 2388.4
V3HxBc2 P313A 4734.5 4734.8 2367.9
V3HxBc2 G314A 4774.5 4774.9 2387.5
V3HxBc2 R315A 4675.4 4675.8 2338.4
V3HxBc2 F317A 4684.4 4684.8 2342.9
V3HxBc2 V318A 4732.4 4732.6 2366.2
V3HxBc2 T319A 4730.5 4730.7 2365.8
V3HxBc2 I320A 4718.4 4718.3 2359.6
V3HxBc2 G321A 4774.5 4774.4 2388.0
V3HxBc2 K322A 4703.4 4707.0 2353.3
V3HxBc2 I323A 4718.4 4722.2 2360.8
V3HxBc2 G324A 4774.5 4777.6 2387.6
V3HxBc2 N325A 4717.5 4721.2 2360.3
V3HxBc2 M326A 4700.4 4703.7 2351.5
buffer pH 7.2 (300µL/well) after each incubation step. Plates
were developed with 100µL/well OPD (1 mg/mL) in the presence
of 0.03% H2O2 for approximately 1.5 min (V3 loop peptide
detection), or 3.5 min (gp120 detection) in the dark. After the
reaction was stopped with 50µL/well 2 M H2SO4, absorbances
were read at 492 nm and corrected for the blank (sample with
biotin instead of CX4-M1). All data points present means of at
least duplicates.
ANTI-V3 mAb ELISA
A streptavidin-coated plate, which was prepared as described
above, was incubated with biotinylated V3 loop peptides at 100 nM
for 2 h. Additionally, a high binding microtiter plate (Immulon
2HB) was coated with gp120 at 8 nM overnight, followed by block-
ing with 1% BSA. Both plates were incubated with anti-V3 loop
mAbs (3869 or 447-52D), respectively, at 2 nM for 3 h. Bound anti-
body was detected using goat anti human HRP conjugate from
Sigma-Aldrich at 1µg/mL. Plates were developed as described
above.
COMPETITIVE ELISA
High binding microtiter plates (Immulon 2HB) were coated
with streptavidin and incubated with CX4-M1 as described
above for the direct ELISA. The anti-V3 loop mAbs 3869 and
447-52D, respectively, were added at twofold serial dilutions
from 150 to 0.3 nM. Plates were then incubated for 3 h with
gp120HxBc2 and sCD4 (each at 12.5 nM), or with V3HxBc2 (50 nM).
Fluoresceinylated V3 loop peptides and gp120 were detected and
plates developed as described above. IC50-values were determined
using the regression wizard of Sigma Plot 9.0. Inhibition was
calculated according to the following formula:
% Inhibition= [1− (Aantibody−Ablank)/(A100%−Ablank)]×100
in which “100%” is a sample with CX4-M1, but without anti-
body, and “blank” is a sample with biotin instead of CX4-M1, and
without antibody.
SURFACE PLASMON RESONANCE
All measurements were performed using a Biacore X100 instru-
ment in conjunction with the Biotin CAPture Kit (both from
GE Healthcare). Sensor chip CAP was hybridized with a 1:10
dilution of CAPture reagent (streptavidin conjugate) in running
buffer. CX4-M1 (2µM) was bound to streptavidin and binding
of V3 loop peptides (5–0.3µM) or gp120 (8–0.5 nM) to CX4-
M1 was measured. For dehybridization, a regeneration solution
of 6 M guanidinium chloride and 250 mM sodium hydroxide
was used. HBS-N buffer (10 mM HEPES, 150 mM sodium chlo-
ride, pH 7.4) containing 0.05% Tween 20, as well as 100 mM
(V3 loop peptides) or 2.5 mM (gp120) magnesium chloride,
was used as running buffer. Measurement and data evalua-
tion was performed using Biacore X100 Control Software (Ver-
sion 2.0) and Biacore X100 Evaluation Software (Version 2.0),
respectively.
REPORTER CELL ASSAY
The indicator cell line CEMx174, which was kindly provided by
Means and Desrosiers, contained the gene for the secreted alkaline
phosphatase (SEAP) under the control of the simian immun-
odeficiency virus long terminal repeat (19). The suitability of
this cell line for HIV-1 drug resistance testing has been eval-
uated extensively (20). Peptides were added to the cells prior
to addition of HIV-1NL4-3. Three days after infection, cell cul-
ture supernatants were removed and analyzed for SEAP activ-
ity using the Phospha-Light kit (Life Technologies, Darmstadt,
Germany) according to the manufacturer’s instructions. Data
represent mean and standard error of at least three indepen-
dently performed experiments, which were all carried out in
triplicates.
RESULTS AND DISCUSSION
We have recently shown that the CXCR4 mimetic peptide CX4-
M1 selectively binds to gp120 from X4 tropic HIV-1 (15). Since
the coreceptor tropism of HIV-1 is largely located in the V3 loop of
gp120 (21), we now asked the question whether the X4-selective
interaction of CX4-M1 with gp120 could be reproduced in its
interaction with peptides presenting the V3 loops of X4-tropic
gp120. In order to answer this question, we prepared peptides pre-
senting the V3 loops of gp120 from three X4-tropic (IIIB, HxBc2,
MN) and two R5-tropic (BAL and ADA) HIV-1 strains (Figure 2;
Table 3). These peptides were tested in a direct ELISA for their
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Table 2 | ESI-mass spectrometry data of synthesized peptides.
Peptide Mcalc (g/mol) [M+H]+ [M+2H]2+ [M+3H]3+ [M+4H]4+ [M+5H]5+ [M+6H]6+ [M+7H]7+ [M+8H]8+
CX4-M1 7136.3 1785.7 1428.5 1190.7 1020.8 893.1
D182A 7092.4 1773.6 1419.8 1183.2 1014.1 887.5
R183A 7050.1 1763.9 1410.5 1175.7
Y184A 7044.5 1762.5 1410.0 1174.9 1007.1 881.7
I185A 7094.2 1773.9 1419.8 1183.3 1014.4 887.8
D187A 7092.4 1418.8 1182.2 1013.6
R188A 7050.1 1410.6 1175.7 1007.8
F189A 7060.3 1765.9 1413.1 1177.6 1009.9 883.8
Y190A 7044.5 1762.1 1410.0 1174.9 1007.4 881.6
P191A 7110.3 1778.8 1422.9 1186.1 1016.9 890.1
N192A 7093.3 1774.5 1419.3 1183.2 1014.2 887.7
D193A 7092.4 1418.9 1182.7 1014.0
L194A 7094.3 1774.8 1419.8 1183.3 1014.5 887.8
W195A 7021.2 1756.3 1405.0 1171.2 1004.1 878.6
V196A 7108.3 1778.1 1422.5 1185.5 1016.2 889.7
V3HxBc2 turn 1585.7 1588.0 794.6 530.4 397.7
V3HxBc2 turn/beta 2585.0 1292.7 862.5 647.4 517.8
V3HxBc2 ∆beta 3761.2 1255.0 941.7 754.0 628.4 539.0 471.3
FIGURE 2 | HPLC chromatogram and MALDI-TOF mass spectrum of purified fluoresceinylated V3HxBc2. (M =4760.6).
ability to bind to CX4-M1 (Figure 3). CX4-M1 recognized the V3
loop peptides (Figure 3B) with a selectivity similar to that seen
for its interaction with gp120 (Figure 3A), i.e., V3 loop peptides
derived from X4-tropic HIV-1 were bound much stronger than
the respective R5-peptides.
During HIV-1 entry into cells, the interaction of HIV-1 gp120
and coreceptor is contingent on prior contact with CD4, which
opens up the gp120 conformation, exposing its coreceptor bind-
ing site, which includes the V3 loop (11). Likewise, binding of
gp120 to CX4-M1 can be enhanced by soluble CD4 (sCD4)
(15). The interaction of X4-V3 loop peptides with CX4-M1,
on the other hand, should be independent on the presence of
sCD4, since in this interaction the V3 loop is not conforma-
tionally masked within gp120, i.e., it is exposed right from the
start. This could be experimentally confirmed in binding exper-
iments in the presence and absence of sCD4, which clearly
showed that, unlike its interaction with gp120, binding of CX4-
M1 to V3 loop peptides does not need enhancement by sCD4
(Figure 4).
Using surface plasmon resonance measurements, we could
show that CX4-M1 binds to gp120 from X4 tropic HIV-1 strains, as
well as to the respective V3 loop peptides, with K d values in the low
to submicromolar range (Figure 5; Table 4). On the other hand,
no binding was detected to gp120, or to the respective V3 loop
peptides, from R5-tropic HIV-1 strains. Apart from re-confirming
the tropism selectivity of the CX4-M1–gp120 interaction, these
results also indicate that HIV-1 coreceptor tropism can be repro-
duced in V3 loop peptides. It should be noted, however, that, unlike
in the ELISA experiments described above, no sCD4 was present in
these SPR experiments. As shown before (Figure 4), sCD4 dramat-
ically enhances the interaction of gp120HxBc2 with CX4-M1, likely
by inducing proper exposure of the V3 loop. This phenomenon
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Table 3 | Sequences of V3 loop peptides.able 3. S quences of V3 loop peptides.  
   296CTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHC331     V3 loop of HIV-1HxBc2
       β-strand      turn      β-strand 
Peptide Sequence
V3 LOOP PEPTIDES (WT)
V3IIIB Fluoa-Xb-G-X-CTRPNNNTRKKIRIQRGPGRAFVTIGKIGNMRQAHC-NH2
V3HxBc2 Yc-X-G-X-CTRPNNNTRKRIRIQRGPGRAFVTIGKIGNMRQAHC-NH2
V3MN Fluo-X-G-X-CTRPNYNKRKRIHI–GPGRAFYTTKNIIGTIRQAHC-NH2
V3BAL Yc-X-G-X-CTRPNNNTRKSIHI–GPGRALYTTGEIIGDIRQAHC-NH2
V3ADA Fluo-X-G-X-CTRPNNNTRKSIHI–GPGRAFYTTGEIIGDIRQAHC-NH2
TRUNCATED VARIANTS of V3HxBc2
V3HxBc2 turn Fluo-X-G-X————-CdQRGPGRACd—————NH2
V3HxBc2 turn/beta Fluo-X-G-X———CdRIRIQRGPGRAFVTICd———–NH2
V3HxBc2 ∆beta Fluo-X-G-X-CTRPNNNTRK—-QRGPGRA—GKIGNMRQAHC–NH2
ALANINE SCAN of V3HxBc2
V3HxBc2 R306A Fluo-X-G-X-CTRPNNNTRKAIRIQRGPGRAFVTIGKIGNMRQAHC-NH2
V3HxBc2 I307A Fluo-X-G-X-CTRPNNNTRKRARIQRGPGRAFVTIGKIGNMRQAHC-NH2
V3HxBc2 R308A Fluo-X-G-X-CTRPNNNTRKRIAIQRGPGRAFVTIGKIGNMRQAHC-NH2
V3HxBc2 I309A Fluo-X-G-X-CTRPNNNTRKRIRAQRGPGRAFVTIGKIGNMRQAHC-NH2
V3HxBc2 Q310A Fluo-X-G-X-CTRPNNNTRKRIRIARGPGRAFVTIGKIGNMRQAHC-NH2
V3HxBc2 R311A Fluo-X-G-X-CTRPNNNTRKRIRIQAGPGRAFVTIGKIGNMRQAHC-NH2
V3HxBc2 G312A Fluo-X-G-X-CTRPNNNTRKRIRIQRAPGRAFVTIGKIGNMRQAHC-NH2
V3HxBc2 P313A Fluo-X-G-X-CTRPNNNTRKRIRIQRGAGRAFVTIGKIGNMRQAHC-NH2
V3HxBc2 G314A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPARAFVTIGKIGNMRQAHC-NH2
V3HxBc2 R315A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGAAFVTIGKIGNMRQAHC-NH2
V3HxBc2 F317A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGRAAVTIGKIGNMRQAHC-NH2
V3HxBc2 V318A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGRAFATIGKIGNMRQAHC-NH2
V3HxBc2 T319A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGRAFVAIGKIGNMRQAHC-NH2
V3HxBc2 I320A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGRAFVTAGKIGNMRQAHC-NH2
V3HxBc2 G321A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGRAFVTIAKIGNMRQAHC-NH2
V3HxBc2 K322A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGRAFVTIGAIGNMRQAHC-NH2
V3HxBc2 I323A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGRAFVTIGKAGNMRQAHC-NH2
V3HxBc2 G324A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGRAFVTIGKIANMRQAHC-NH2
V3HxBc2 N325A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGRAFVTIGKIGAMRQAHC-NH2
V3HxBc2 M326A Fluo-X-G-X-CTRPNNNTRKRIRIQRGPGRAFVTIGKIGNARQAHC-NH2
aFluo, fluorescein; bX, ε-aminohexanoic acid (spacer); cY, fluorescein or biotin; dadditional cysteine residues forming a disulfide bridge.
is apparently less pronounced for gp120IIIB than for gp120HxBc2,
since the former protein has an approximately 10-fold higher affin-
ity to CX4-M1 than the respective V3 loop peptide, even when no
sCD4 is present (Table 4). Regardless of these differences, it is
likely that, in the presence of sCD4, the K D values for the X4
tropic gp120–CX4-M1 interactions would be considerably lower
than those for the respective V3 loop peptide interactions.
The sequences of the gp120 V3 loops of very few HIV-1 strains,
including IIIB and HxBc2, contain an additional QR dipeptide,
which is inserted in the central region of the sequence (see Table 3,
first two entries). The presence or absence of this QR insert (+QR
vs. −QR) is irrelevant for coreceptor tropism, however, we have
found that it is reflected in the binding selectivity of antibodies
that recognize the V3 loop. MAb 447-52D, for example, recognizes
both +QR and −QR V3 loops, such as HxBc2 and BAL, whereas
mAb 3869 is selective for −QR V3 loops (Figure 6A). We have
used these two antibodies to further substantiate the mimicry of
binding selectivity of gp120 in its interaction with CX4-M1, by
V3 loop peptides. In competition experiments we could show that
mAb 447-52D, but not mAb 3869, is able to compete with CX4-M1
for binding to gp120HxBc2 (Figure 6B), as well as to the respec-
tive V3 loop peptide (Figure 6C). These results provide further
evidence for selectivity in binding of not only gp120, but also V3
loop peptides, to the CXCR4 mimetic peptide CX4-M1, and thus
for a functional mimicry of the gp120–CXCR4 interaction, by the
V3 loop–CX4-M1 interaction.
Having established the V3 loop–CX4-M1 interaction as a valid
model for the gp120–CXCR4 interaction, we set out to characterize
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FIGURE 3 | Binding of gp120 (in the presence of sCD4) (A) and V3 loop peptides (B) from X4 tropic (IIIB, HxBc2, and MN) and R5-tropic (BAL and ADA)
HIV-1 to the CXCR4 mimetic peptide CX4-M1. See Section “Materials and Methods” (direct ELISA) for experimental detail. Error bars present deviations
from the mean.
FIGURE 4 | Binding of the CXCR4 mimetic peptide CX4-M1 to gp120HxBc2 (A) and the V3 loop peptide V3HxBc2 (B), in the presence and absence,
respectively, of sCD4. See Section “Materials and Methods” (direct ELISA) for experimental detail. Error bars present deviations from the mean.
FIGURE 5 | Surface Plasmon resonance sensograms for the interaction of the CXCR4 mimetic peptide CX4-M1 with V3 loop peptides from X4 tropic
(HxBc2) (A) and R5-tropic (ADA) (B) HIV-1. See Section “Materials and Methods” for experimental detail.
it at the level of individual amino acids. While peptides present-
ing the V3 loop are intrinsically unfolded (22–24), the sequence
stretch covering residues 306–320 of gp120, which is located in the
central region at the tip of the V3 loop, adopts a defined secondary
structure in an antibody-bound stage. This was shown by NMR
spectroscopy and X-ray crystallography of several complexes of
V3 loop peptides with antibodies whose epitopes were mapped
to the V3 loop (25–34). In these complex structures, residues
306–309, as well as 317–320, form strands of a small beta sheet,
which are connected by the turn region located in amino acids
310–316 (HxBc2 nomenclature). In order to dissect the contribu-
tion of these V3 loop fragments to the interaction with CX4-M1,
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truncated variants of V3HxBc2 were generated, which present only
the turn region (V3HxBc2 turn), or the turn region and the two beta
strands (V3HxBc2 turn/beta), as well as a peptide in which the two
beta strands were omitted (V3HxBc2 ∆beta). In order to facilitate
a possible formation of the turn and beta sheet, the sequences of
V3HxBc2 turn and V3HxBc2 turn/beta were flanked by additional
cysteine residues, which were connected by disulfide bridges, gen-
erating covalently stabilized loops. Of the three truncated V3HxBc2
variants, only V3HxBc2 turn/beta retained some of the affinity of
V3HxBc2 to CX4-M1 (Figure 7), suggesting a contribution of the
beta strands to the interaction with CX4-M1, since their omission
in peptides V3HxBc2 turn and V3HxBc2 ∆beta resulted in a complete
loss of binding to CX4-M1.
The importance of the two beta strand fragments for the inter-
action with CX4-M1 could be confirmed using peptides presenting
an alanine scan of residues 306–326 of V3HxBc2 (Table 3). This
Table 4 | Affinities of CX4-M1 to gp120 and V3 loop peptides,
respectively, from X4 tropic and R5-tropic HIV-1.
HIV-1 strain (tropism) K D (gp120) K D (V3 loop peptide)
IIIB (X4) 0.1µM 1.1µM
HxBc2 (X4) 0.2µM 0.3µM
MN (X4) 0.7µM 1.6µM
ADA (R5) No binding No binding
BAL (R5) No binding No binding
segment presents the complete V3 loop except for the N- and
C-termini (residues 296–305 and 327–331, respectively), which
are conserved, regardless of coreceptor tropism (35). Similar
to the truncated V3HxBc2 variants, binding data obtained for
these peptides point to a strong contribution of the beta strands
to the interaction of V3HxBc2 with CX4-M1, since replacement
of these residues, in particular I307, R308, I309, F317, V318,
and I320, with alanine, strongly diminished binding to CX4-
M1 (Figure 8). This result may suggest that the beta sheet in
the V3 loop peptides, which is seen in V3 loop-antibody com-
plexes, could be reproduced in the CX4-M1 – bound state of
the V3 loop peptides, and that this beta sheet may possibly
be affected by modifying the amino acids constituting the beta
strands.
Since the second extracellular loop (ECL2) of CXCR4 is cru-
cial for the interaction of this coreceptor with HIV-1 gp120 (36),
we set out to dissect the determinants of this loop, at the level
of individual amino acids, using CX4-M1 as a CXCR4 mimic.
Binding and infection assays involving cells that express CXCR4
containing alanine mutations in ECL2 had previously indicated
that replacing acidic residues D187 and D193 with alanine had an
inhibitory effect (37). These effects were further confirmed in dou-
ble mutants, in which an aspartate (D187) and a tyrosine residue
(Y190) were both replaced by alanine (38). Furthermore, a charge
dependency in the interaction of the V3 loop with CXCR4 is highly
likely, since the X4-tropism of V3 loops strongly depends on the
presence of positively charged amino acids in positions 306, 321,
and/or 322 (HxBc2 nomenclature) (39).
FIGURE 6 | Binding of gp120 and V3 loop peptides from HIV-1
strains HxBc2 (+QR) and BAL (−QR), to mAbs 3869 and 447-52D
(A). Dose-dependent effect of mAbs 447-52D and 3869, respectively,
on binding of gp120HxBc2 (in the presence of sCD4) (B) and the
respective V3 loop peptide (V3HxBc2) (C), to the CXCR4 mimetic peptide
CX4-M1. See Section “Materials and Methods” (anti-V3 mAb ELISA
and Competitive ELISA) for experimental detail. Error bars present
deviations from the mean.
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Using an alanine scan of ECL2 in the context of CX4-M1
(Table 5), we identified positively charged ECL2 residues, such
as R183 and R188, but also I185, F189, P191, and N192, whose
replacement with alanine enhanced binding to gp120 from X4
tropic HIV-1HxBc2 (Figure 9A). Replacement of other ECL2
residues (D182, D187, D193, L194A, W195) with alanine, on the
other hand, had a negative effect on the affinity, indicating their
importance for the CX4-M1–gp120 interaction (Figure 9A). Inter-
estingly, a similar, yet not identical pattern could be seen for the
interaction of the ECL2 alanine scan of CX4-M1 with the V3 loop
of gp120HxBc2 (Figure 9B). The inhibitory effect on binding of
decreasing the negative net charge of CX4-M1, by replacing one
of the three acidic residues of ECL2 (D182, D187, and D193) with
alanine, was clearly seen also in its interaction with theV3HxBc2. On
the other hand, enhancement of binding to V3HxBc2 was seen not
FIGURE 7 | Binding of V3HxBc2 and its truncated variants to the CXCR4
mimetic peptide CX4-M1. See Section “Materials and Methods” (direct
ELISA) for experimental detail. Error bars present deviations from the mean.
only in R183A, R188A, I1854, F189, P191A, and N192A, but also
in CX4-M1 variants with alanine mutations at aromatic residues
(Y184 and Y190), as well as hydrophobic residues L194 and V196.
Moreover, we detected a converse behavior of CX4-M1 variants
Y184A, Y190A, and L194A, with attenuated binding to gp120,
while binding to the V3 loop peptide was enhanced. These dif-
ferences may have their origin in the different flexibility of the
V3 loop in gp120 and the V3 loop peptide, respectively, in that
the larger flexibility of the V3 loop peptide may be able to com-
pensate for the complementarity constraints imposed by alanine
mutations in CX4-M1. Furthermore, post-translational modifica-
tions in the V3 loop of gp120, such as N -linked glycosylation of
asparagine residues (40), may also be a factor contributing to the
differences in binding of some CX4-M1 variants to gp120 and the
respective V3 loop peptide. In addition, the V3 loop is not the
only part of gp120 that interacts with the coreceptor. Other gp120
regions, including the bridging sheet and the V1/V2 loop, also play
a role in this interaction, even when the N-terminus of CXCR4,
which is thought to bind to the bridging sheet, is deleted (41).
Since the V1/V2 loop is not present in V3 loop peptides, the dif-
ferent binding pattern of CX4-M1 alanine variants to gp120 and
V3 loop peptides may indicate interactions of the V1/V2 loop also
with ECL2 of CXCR4.
Taken together, these data support, at the level of peptide–
protein and peptide–peptide interactions, the notion of a negative
net charge of ECL2 of CXCR4 being critical for its interaction
with the positively charged V3 loop of gp120 from X4-tropic HIV-
1. Furthermore, these data demonstrate how variants of mimetic
peptides can be used to gain information on a protein–protein
interaction when peptide–peptide interactions are looked at in
the context of the respective peptide–protein interaction.
We have previously shown that CX4-M1 not only selectively
binds to X4 tropic gp120, but also selectively inhibits infection of
cells with X4-tropic HIV-1 (15). This inhibition is thought to be
FIGURE 8 | Effect of alanine substitutions in V3HxBc2 on binding to the
CXCR4 mimetic peptide CX4-M1. See Section “Materials and Methods”
(direct ELISA) for experimental detail. Relative absorbances (Ar) were
calculated according to the following formula: Ar = (Apeptide −Ablank)/(Ac −Ablank),
in which “peptide” refers to the respective variant of V3HxBc2, and “c” refers to
V3HxBc2. Error bars present deviations from the mean.
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Table 5 | Alanine substitution variants of the CXCR4 mimetic peptide CX4-M1.
   97DAVANWYFGNFLCK110       182 DRYICDRFYPNDLWV196       262DSFILLEIIKQGSEFENTVHK282
      ECL1      ECL2        ECL3 
Peptide Sequence
CX4-M1 Aca-ECL1-Xb-Bc-X-ECL2-X-B-X-ECL3-X-K(Biod)-NH2
Alanine substitution variants of ECL2 of CX4-M1
CX4-M1 D182A Ac-ECL1-X-B-X-ARYICDRFYPNDLWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 R183A Ac-ECL1-X-B-X-DAYICDRFYPNDLWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 Y184A Ac-ECL1-X-B-X-DRAICDRFYPNDLWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 I185A Ac-ECL1-X-B-X-DRYACDRFYPNDLWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 D187A Ac-ECL1-X-B-X-DRYICARFYPNDLWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 R188A Ac-ECL1-X-B-X-DRYICDAFYPNDLWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 F189A Ac-ECL1-X-B-X-DRYICDRAYPNDLWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 Y190A Ac-ECL1-X-B-X-DRYICDRFAPNDLWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 P191A Ac-ECL1-X-B-X-DRYICDRFYANDLWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 N192A Ac-ECL1-X-B-X-DRYICDRFYPADLWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 D193A Ac-ECL1-X-B-X-DRYICDRFYPNALWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 L194A Ac-ECL1-X-B-X-DRYICDRFYPNDAWV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 W195A Ac-ECL1-X-B-X-DRYICDRFYPNDLAV-X-B-X-ECL3-X-K(Bio)-NH2
CX4-M1 V196A Ac-ECL1-X-B-X-DRYICDRFYPNDLWA-X-B-X-ECL3-X-K(Bio)-NH2
aAc, acetyl; bX, ε-aminohexanoic acid; cB, β-alanine; dBio, biotin.
FIGURE 9 | Effect of alanine substitutions in ECL2 of CX4-M1 on
binding to gp120HxBc2 (A) (in the presence of sCD4) and its
corresponding V3 loop peptide (V3HxBc2) (B), respectively. See Section
“Materials and Methods” (direct ELISA) for experimental detail. Relative
absorbances (Ar) were calculated according to the following formula:
Ar = (Apeptide −Ablank)/(Ac −Ablank), in which “peptide” refers to the respective
variant of CX4-M1, and “c” refers to CX4-M1. Error bars present deviations
from the mean.
based on the interaction of CX4-M1 with viral gp120, which pre-
cludes contact of the virus with cellular CXCR4 and, consequently,
intercepts the process of HIV-1 entry. Therefore, we tested V3HxBc2
for its ability to interfere with the infection inhibition caused by
CX4-M1. As shown in Figure 10, CX4-M1 inhibits, at 10µM, the
infection of SEAP cells with the X4 tropic HIV-1NL-4.3 by more
than 90% (white bar). This almost complete inhibition could be
counter-acted, in a dose-dependent manner, by V3HxBc2, restoring
infection of cells with HIV-1 (gray bars). It seems likely that this
effect is due to capture of CX4-M1 by the V3 loop peptide, prevent-
ing binding of CX4-M1 to viral gp120, and, consequently, resulting
in recovery of infection. This result shows that the functional mim-
icry of the gp120–CXCR4 interaction by the V3 loop–CX4-M1
interaction is present not only in binding experiments involving
solely proteins and peptides, but also in the context of an HIV-1
infection.
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FIGURE 10 | Dose-dependent effect of the V3 loop peptide V3HxBc2 on
the CX4-M1 – induced inhibition of infection of CEMx174 cells with
HIV-1NL4-3. See Section “Materials and Methods” (reporter cell assay) for
experimental detail. Error bars present standard errors of the mean (SEM).
CONCLUSION
In conclusion, using direct and competitive binding assays, as
well as an HIV-1 infection assay, we have provided experimental
evidence indicating that the interaction of the HIV-1 glycopro-
tein gp120 with its cellular coreceptor CXCR4 can be functionally
mimicked by peptides presenting essential parts of the binding
sites of the two proteins for each other, i.e., the V3 loop of gp120
and the three ECLs of CXCR4. Furthermore, truncated and sub-
stitution variants of the mimetic peptides were used to explore
this interaction at the level of individual amino acids, the results
of which may be relevant for the analysis of the gp120–CXCR4
interaction as well. Ongoing and future research will be aimed
at elucidating the structural basis of this interaction, as well as
on probing the concept of mimicking protein–protein interac-
tions by peptide–peptide interactions in the context of other
proteins.
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